Government News

Join WhatsApp Channel 

Regulatory Affairs Courses

  •  Ministry of Health and Family Welfare, Government of India signed a Letter of Intent with the Norwegian Ministry of Foreign Affairs, Government of Norway to extend the cooperation within health sector through the Norway India Partnership Initiative (NIPI) for a period of three years starting from 2018, here today. Shri C K Mishra, Secretary (HFW) and His Excellency, Mr. Nils Ragnar Kamsvag, Ambassador of Norway signed this Letter of Intent. Shri Manoj Jhalani, Additional Secretary & Mission Director (AS&MD), Ms. Vandana Gurnani, JS (RCH), Dr. Tore Godal, Special Adviser to Prime Minister of Norway, Dr Maha-noor Khan, Ministry of Foreign Affairs, Norway were also present during the signing ceremony.

  • The Ministry of Health and Family Welfare has launched two new contraceptives, an injectable contraceptive MPA under the ‘Antara’ programme and a contraceptive pill, ‘Chhaya’, in the public health system to expand the basket of contraceptive choices to meet the emerging needs of couples. The contraceptives, which are available for free in Medical Colleges and District Hospitals at present, have so far been launched in 10 states that includes Maharashtra, Uttar Pradesh, Madhya Pradesh, Rajasthan, Karnataka, Haryana, West Bengal, Odisha, Delhi and Goa. The contraceptives are safe and highly effective, the ‘Antara’ injectable being effective for three months and the ‘Chayya’ pill for one week, and will help meet the changing needs of couples and help women plan and space their pregnancies. Training of healthcare practitioners from all the states has been completed as well, with a pool of state and district level doctors and staff nurses being trained to support the roll-out.

  • A first ever breakthrough in the area of osteoarthritis, a most common chronic condition of the joints that afflicts mainly the weight-bearing joints such as hips and knees, and causes physical disabilities. At present there is no viable treatment available for osteoarthritis. CDRI(Central Drug Research Institute) Scientists has developed a standardized nano-formulation from Spinaceaoleracea commonly known as Palak for treatment of osteoarthritis. And it is patented for formulation of Spinaceaoleracea for the prevention  and /or treatment of bone related disorders by CDRI

    [adsense:336x280:8701650588]

  • Dr. Rao Vadlamudi, President of Indian Pharmaceutical Association (IPA), has been elected as President of Commonwealth Pharmacists Association (CPA) for the year 2017-19 at CPA Conference held at Hyatt Regency, Sydney, Australia from 28 - 30, July 2017. Dr. Rao Vadlamudi is the second Indian professional to be elected as CPA President after a gap of 30 years.

  • Central Drugs Standard Control Organization (CDSCO) emphasize on GMP and GLP compliance to pharmaceutical manufacturers. But it seems like pharma manufacturers are not serious about implementation of GMP and GLP for their manufacturing plants. Before one year, CDSCO asked manufacturers to carry out an assessment of their units and assign themselves quality ratings but so far Indian pharma manufacturers have not submitted self-inspection reports.

  • Only people who hold a MBBS degree and are enrolled in the (MCI) or state medical councils can now sign diagnostic reports, according to a new order issued by. The movement is aimed at regulating the quality and standard of reports generated by diagnostic chains, which multiply rapidly across the country.

  • The Ministry of Health has notified the Medical Devices Provisions, 2017, which will come into effect from January 2018. The government has also notified 15 devices, as the drugs automatically bring them under strict price control. In addition to catheters, stents and orthopedic implants, the list also includes heart valves, intraocular lenses, syringes, and needles.

    [adsense:336x280:8701650588]

  • In an effort to create a globally competitive biopharmaceutical industry that addresses the countrys major concerns about barriers to affordable healthcare, the Department of Biotechnology (DBT) has launched the Innovate in India (i3) program, As well as the systemic support to pursue their aspirations in biotechnological innovation, and to transform India into a global hub for cutting-edge biotechnology research and development.

    A collaborative mission between industry and academia to accelerate discovery research for the early development of biopharmaceuticals, this USD 250 million DBT program is a unique mission that brings together industry and academia to promote entrepreneurship and Indigenous manufacturing in the biopharmaceutical sector.

    This collaborative mission between industry and academia is expected to change the game for the Indian biopharma industry. This flagship program of the DBT, in collaboration with the World Bank, will be implemented by the Biotechnology Industry Research Assistance Council (BIRAC) of the DBT.

    The program will specifically focus on the development of new vaccines, bio-therapeutics, diagnostics and medical devices to better address the growing burden of disease in the country. It will also bring together isolated centers of excellence, improve regional capacities and strengthen the existing network of bio-clusters in terms of capacity as well as quantity and quality of production.

    The program aims to create an ecosystem conducive to promoting entrepreneurship and indigenous manufacturing in the sector. It will help nurture the next generation of technical skills; Promoting entrepreneurship; And support institutions in adopting innovations, technologies and models of global licenses. The program will help deliver 6 to 10 new products over the next five years, create several dedicated facilities for next-generation skills and hundreds of jobs in the process. It will provide young entrepreneurs with the confidence and systemic support to pursue their aspirations in biotechnological innovation and transform India into a world center of research and development.

    As a flagship program of the Government of India in collaboration with the World Bank, it promises to boost the national biopharma growth curve in India by accelerating the translation of research concepts to viable products, supporting clinical validation, enabling sustainable networks of collaboration between industry And Academy and supporting business ecosystems among many others.


    Currently India has only 2.8% share in the global biopharmaceutical market, the program would elevate this to 5% resulting in an additional business opportunity of 16 billion USD.

    The Monitoring of the program would be provided by the Interministerial Steering Committee composed of members from various Ministries; And it would have the support of the Technical Advisory Group of the Program composed of world and national leaders of the industry and the academic world. Therefore, the program is unique in its approach with the participation of global experts, industry leaders and the World Bank in its drive and ensuring that world-class biomedical products are born out of the initiative.

    << Back to Pharma News

    Subscribe to PharmaTutor News Alerts by Email

Subscribe to Government News